Table 2.
ADAMTS | Endogenous Inhibitor | Synthetic Inhibitor | Reference | ||||||
---|---|---|---|---|---|---|---|---|---|
1 | Material | Category | Action type | Molecular target | Material | Category | Action type | Molecular target | [27] |
TIMP-2 | Tissue inhibitor of metalloproteinase | Binding inhibition | 3N-terminal globular domain of aggrecan (G1) | 1,10-phenanthroline | Organic small molecule | Binding inhibition | Urin recognition site (RX(K/R)R) (33, 34) | ||
TIMP-3 | EDTA | ||||||||
BB-94 | |||||||||
2 | TIMP-3 | Tissue inhibitor of metalloproteinase | Binding inhibition | Sulfated glycosaminoglycans associated with ECM and cell surfaces | TBD | [216,217,218,219] | |||
Cu2+ | Metal ion | Bound zinc blinding zone | |||||||
α−2 macroglobulin | Enzyme | ||||||||
Paplin | Protein | Non-competitive inhibition | |||||||
3 | TIMP-3 | Tissue inhibitor of metalloproteinase | Binding inhibition | Sulfated glycosaminoglycans associated with ECM and cell surfaces | TBD | [218] | |||
Cu2+ | Metal ion | Bound zinc blinding zone | |||||||
4 | TIMP-3 | Tissue inhibitor of metalloproteinase | Binding inhibition | Glu1480–Gly1481 bond | Cis-1(S)2(R)-amino-2-indanol-based | Organic small molecule | Selective action | Water bridging, ring rigidity, pocket size, and shape | [217,220,221] |
α−2 macroglobulin | Enzyme | 691GRGHAR | Metformin | ||||||
PTH1-34 | Hormone | IGF/IGFBP | Losartan | Signal conditioning | TGF-β1 | ||||
β-Ecdysone | FOXO1/ADAMTS-4/5 | ||||||||
4,5-Dicaffeoylquinic Acid | NF-κB | ||||||||
Matrix protein CCN1 | Protein | TGF-β/CCN1 | |||||||
5 | Matrix protein CCN1 | Protein | Binding inhibition | TGF-β/CCN1 | Cis-1(S)2(R)-amino-2-indanol-based | Organic small molecule | Selective action | Water bridging, ring rigidity, pocket size, and shape | [217,220,221,222,223,224,225,226] |
TIMP-3 | Tissue inhibitor of metalloproteinase | Glu1480–Gly1481 bond | Metformin | ||||||
α−2 macroglobulin | Enzyme | YESDVM690 | 4,5-Dicaffeoylquinic Acid | Organic acid | Signal conditioning | NF-κB | |||
PTH1-34 | Hormone | IGF/IGFBP | Glycoconjugated arylsulfonamide | Binding inhibition | Exosite | ||||
Losartan | Signal conditioning | TGF-β1 | |||||||
β-Ecdysone | FOXO1/ADAMTS-4/5 | ||||||||
5-((1H-pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors | Binding inhibition | MicroM | |||||||
7 | TIMP-4 | Tissue inhibitor of metalloproteinase | Binding inhibition | Active site zinc | Granulin-epithelin precursor | Protein | Binding inhibition Binding inhibition |
Carboxy-terminal TSR motifs of ADAMTS7 and 12 | [76,217,227,228] |
GEP | Protein | C-terminal thrombospondin motifs | JG23 | Organic acid | IC, cut | ||||
EDV33 | Combined with zinc ion | ||||||||
8 | TBD | LIPUS | Pulse | Electrotherapy | ZNT-9 | [229,230,231] | |||
12 | TIMP-4 | Tissue inhibitor of metalloproteinase | Binding inhibition | Active site zinc | Granulin-epithelin precursor | Protein | Binding inhibition | Carboxy-terminal TSR motifs of ADAMTS7 and 12 | [76,217,227,228] |
α2-M | Enzyme | ||||||||
GEP | Protein | C-terminal thrombospondin motifs | |||||||
14 | TIMP-3 | Tissue inhibitor of metalloproteinase | Binding inhibition | Sulfated glycosaminoglycans associated with ECM and cell surfaces | TBD | [218] | |||
Cu2+ | Metal ion | Bound zinc blinding zone |